¿Cómo paga?

Cómo pagar lo menos posible

Pregunte el precio sin seguro

Opdivo Qvantig

Opdivo Qvantig es un medicamento biológico. Los biológicos no tienen genéricos, pero algunos tienen biosimilares o una versión sin marca del mismo fabricante. Pregúntele a su farmacéutico o a su médico si se vende alguno.

Qué hacer

  1. Pregunte en su farmacia el precio sin seguro de Opdivo Qvantig, y también en una o dos farmacias más.
  2. La tarjeta de ahorro de Opdivo Qvantig solo funciona con un seguro del trabajo o uno que usted compró.

Otras opciones

Gratis del fabricante, si cumple los requisitos Bristol Myers Squibb Patient Assistance Foundation (BMSPAF). O llame al 1-800-736-0003.

Ver si cumple los requisitos 

Compare todas las opciones

De marca

Opdivo Qvantig, el original

Sin seguroPregunte en la farmacia
Formas de ahorrar en Opdivo Qvantig

La tarjeta del fabricante

BMS Access Support Co-Pay Assistance Program

Tarjeta de ahorro de Bristol Myers Squibb

Sin seguroRequiere seguroNo tiene precio sin seguro.
Con seguro $0 por dosis

Inscríbase en bmsaccesssupport.com 

O llame al 1-800-861-0048.

En palabras del fabricante (en inglés)

“$0 Co-pay per dose…”

De la oferta del fabricante en bmsaccesssupport.com, revisada el 17 de noviembre de 2026. Las tarjetas de copago no se pueden usar con Medicare (incluido Medicare Advantage), Medicaid, TRICARE ni VA.

¿Tarjeta del fabricante o tarjeta de descuento?

Una tarjeta de descuento como GoodRx baja el precio sin seguro de la farmacia, pero para un medicamento de marca ese precio muchas veces sigue siendo alto. Compárelo con la tarjeta del fabricante que aparece arriba. Por lo general, puede usar una u otra al surtir su receta, no las dos.

Genérico autorizado

No existe ninguno.

No se vendeNo existe ninguno

Genérico regular

Opdivo Qvantig es un medicamento biológico. Los biológicos no tienen genéricos, pero algunos tienen biosimilares o una versión sin marca del mismo fabricante. Pregúntele a su farmacéutico o a su médico si se vende alguno.

No se vendePregunte en la farmacia

Para qué se usa

Lo que dice la etiqueta de la FDA (en inglés)

OPDIVO QVANTIG is a combination of nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of:

Renal Cell Carcinoma (RCC)

  • adult patients with intermediate or poor risk advanced RCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab.
    • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of renal cell carcinoma.
  • adult patients with advanced RCC, as a first-line treatment in combination with cabozantinib.
  • adult patients with advanced RCC who have received prior anti-angiogenic therapy.

Melanoma

  • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma.
  • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma following combination treatment with intravenous nivolumab and ipilimumab.
    • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic melanoma.
  • for the adjuvant treatment of adult and pediatric (12 years and older who weigh 30 kg or greater) patients with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma.

Non-Small Cell Lung Cancer (NSCLC)

  • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC in the neoadjuvant setting, in combination with platinum-doublet chemotherapy.
  • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by OPDIVO QVANTIG monotherapy as adjuvant treatment after surgery.
  • adult patients with metastatic NSCLC and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO QVANTIG.
    • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of metastatic NSCLC.

Squamous Cell Carcinoma of the Head and Neck (SCCHN)

  • adult patients with recurrent or metastatic SCCHN with disease progression on or after a platinum-based therapy.

Urothelial Carcinoma (UC)

  • adjuvant treatment of adult patients with UC who are at high risk of recurrence after undergoing radical resection of UC.
  • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine.
  • adult patients with locally advanced or metastatic UC who:
    • have disease progression during or following platinum-containing chemotherapy.
    • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Colorectal Cancer (CRC)

  • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), following combination treatment with intravenous nivolumab and ipilimumab.
    • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC.
  • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with MSI-H or dMMR metastatic CRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
    • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC.

Hepatocellular Carcinoma (HCC)

  • adult patients with unresectable or metastatic HCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab.
  • adult patients with unresectable or metastatic HCC, who have been previously treated with sorafenib, following combination treatment with intravenous nivolumab and ipilimumab.
    • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic HCC.

Esophageal Cancer

  • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT).
  • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) as first-line treatment in combination with fluoropyrimidine- and platinum-containing chemotherapy whose tumors express PD-L1 (≥1).
    • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of patients with unresectable advanced or metastatic ESCC.
  • adult patients with unresectable advanced, recurrent or metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy.

Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma

  • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy.

Fuente: la etiqueta de la FDA de Opdivo Qvantig (E.R. Squibb & Sons, L.L.C.), 12 de mayo de 2026. Etiqueta completa en DailyMed 

Datos útiles

  • “Seguro comercial” quiere decir un plan de su trabajo, del Mercado de Seguros Médicos o uno que usted compra por su cuenta. Un plan para jubilados que forma parte de Medicare cuenta como Medicare. Las tarjetas de copago no se pueden usar con Medicare (incluido Medicare Advantage), Medicaid, TRICARE ni VA.
  • La mayoría de las tarjetas requieren inscribirse en el sitio web del fabricante, y muchas solo funcionan si su plan cubre el medicamento. Después, dé los datos de la tarjeta a su farmacia.
  • No deje ni cambie un medicamento sin hablar con su farmacéutico o su médico.